Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Leuk Res. 2015 May 12;39(8):822–827. doi: 10.1016/j.leukres.2015.05.002

Table 2.

Treatments and clinical outcomes of all MPN/LPN patients (n=34)

LPN prior MPN, patients # 1–16
LPN-MPN
type 		Time
between
LPN-MPNa 		LPN
status at
time of
MPN 		LPN treatment type
Initial (I)/ After 2nd DX (II) 		MPN treatment
type 		Treatment
response
LPN (II RX)/
MPN 		DX status at LFU
LPN/ MPN 		Overall
outcome 		Cause of
death
NHL-MPN 14 CR cht, NOS investigational -- UNK UNK UNK UNK Died UNK
NHL-MPN 3 CR CHOP -- -- CR UNK CR UNK Alive
NHL-MF 7 months CR R-CHOP+ HD MTX -- OBS. CR SD CR SD Alive
NHL-MF 17 CR COP-BLEO, XRT -- INT., THAL., HU, Imatinib, 6-MP CR PD CR PD Died MF-AML
NHL-MF 6 CR CHOP, XRT -- HU, AlloSCT CR CR CR CR Alive
NHL-PV 18 CR CHOP -- PEG. CR CR CR CR Alive
MM-MF 10 CR VAD, THAL. -- HU, THAL. CR CR CR PD Died MF-AML
MM-MPN 1 ON therapy VTD ASCT ASCT CR CR CR CR Alive
HL-MF 3 CR NOVP, XRT -- AlloSCT CR CR CR CR Died AlloSCT compl.
HL-HES 12 CR MOPP, XRT -- Imatinib CR NR CR SD Died Heart Failure
HL-PV 37 CR cht, XRT - NOS -- PEG. CR CR CR CR Alive
CLL-MF 3 PD CHLOR, ALEMT. hCVAD, AlloSCT LEN, AlloSCT CR CR CR CR Died AlloSCT compl.
CLL-MF 16 CR FCR -- Ruxolitinib CR CR CR CR Alive
CLL-HES 6 CR FCR FCAR, Dasatinib, FCR+Bev., BR Imatinib PD NR PD CR Died CLL PD
CLL-MF 16 SD OBS. -- OBS. SD SD SD SD Alive
CLL-MF 1 CR BR -- OBS. CR SD CR SD Died UNK
MPN prior LPN, patients # 1–15
MPN-LPN
type 		Time
between
MPN-
LPNa 		MPN
status at
time of
LPN 		MPN treatment type
Initial (I)/ After 2nd DX (II) 		LPN treatment
type 		Treatment response
MPN (II RX)/ LPN 		DX status at LFU
MPN/ LPN 		Overall
outcome 		Cause of
death
ET-NHL 6 CR HU, PEG., HU HU R-EPOCH CR CR CR CR Alive
MF-NHL 10 CR HU Induction + consolidation cht surgery PD CR PD CR Died MF-AML
PV-NHL 4 CR OBS THAL, Imatinib XRT SD CR PD* CR Died UNK
ET-NHL 11 CR INF., HU, ANAG. OBS CHOP, ESHAP, VTEPA, IFO, R-HyperCVAD, UNK PD UNK PD Died NHL PD
ET-NHL 9 SD OBS OBS COPP, CHOPx3, BU, FLU, XRT, HU SD PD UNK* PD Died UNK
PV-NHL 11 CR Inf, HU Ruxolitinib HyperCVAD CR CR CR* CR Alive
PV-NHL 19 CR HU HU R-CHOP CR CR CR CR Alive
ET-NHL 20 SD OBS Induction cht, LEN CHOP, XRT PD CR PD* CR Died UNK
MF-MM 6 SD LEN OBS VCD SD CR PD CR Died MF-AML
MPN-CLL 46 CR HU, ANAG. HU OBS. CR CR CR CR Died UNK
PV-CLL 13 SD OBS OBS cht, NOS SD CR SD* CR Alive
ET-CLL 7 CR HU HU BU CR CR CR CR Died Mts sarcoma
PV-CLL 10 CR HU HU BR CR CR CR UNK Died IM
PV-NHL 10 CR ANAG, PEG. AlloSCT R-CHOP, R-ICE, alloSCT CR CR CR CR Alive
MF-NHL 1 month PD splenectomy AlloSCT splenectomy, AlloSCT CR CR CR CR Alive
MPN concomitant with LPN, patients # 1–3
MPN-LPN
type 		Time
between
MPN-
LPNa 		MPN
status at
time of
LPN 		MPN treatment type
Initial (I)/ After 2nd DX (II) 		LPN treatment
type 		Treatment response
MPN (II RX)/ LPN 		DX status at LFU
MPN/ LPN 		Overall
outcome 		Cause of
death
MF-NHL -- -- -- HU, THAL., Ruxolitinib Rituximab CR CR CR CR Alive
ET-CLL -- -- -- HU OBS. SD CR SD CR Alive
MF-CLL -- -- -- OBS OBS. SD SD SD SD Died UNK
a

Time between MPN and LPN in years, unless otherwise specified,

*

PET or PPV myelofibrosis

Abbr.: cht = chemotherapy; NOS = not otherwise specified; OBS.= observation; XRT = radiotherapy; THAL.= thalidomide; LEN = lenalidomide; CLOR = chlorambucil; ALEMT.= alemtuzumab; HU = hydroxyurea; ANAG.= anagrelide; INF. = interferon alfa; PEG.= pegylated interferon; 6-MP = 6 - mercaptopurine; Bev.= bevacizumab, FLU = fludarabine, AlloSCT = allogeneic stem cell transplantation, ASCT = autologous stem cell transplantation, CR = complete remission, SD = stable disease, UNK = unknown, PD = progression, NR = no response